Observational studyThe journal of headache and pain2026
Eptinezumab to prevent difficult-to-treat migraine: prospective, six-month, real-world multicenter evidence from the GRASP study group.
Observational study in The journal of headache and pain, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Twelve-months prospective real-world assessment of effectiveness and safety of eptinezumab in migraine patients difficult-to-treat and naïve to CGRP monoclonal antibodies: results of the French FHU INOVPAIN registry.The journal of headache and pain · 2026Article
- Cross-response to Calcitonin Gene-Related Peptide monoclonal antibodies in a real-world setting: analysis of prospective data collected in the French FHU InovPain registry.The journal of headache and pain · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe objective of this multicenter, real-world study, designed by the Greek Research Alliance for the Study of headache and Pain (GRASP), was to prospectively evaluate the 6-month effectiveness and safety of eptinezumab 100 mg for migraine prophylaxis in difficult-to-treat patients.
methodsA total of 142 participants (81% female; aged 46.1 ± 12.2 years) with either high-frequency episodic migraine (HFEM) or chronic migraine (CM) were consecutively recruited and received eptinezumab 100 mg quarterly for 6 months (2 cycles). The primary outcome was the proportion of patients who achieved > 50% response at month 3 (T1) and 6 (T2), post-treatment. Secondary outcomes included the changes in monthly migraine/headache days (MMDs/MHDs); monthly days with moderate/severe peak headache intensity; monthly acute medication intake; MIDAS HIT-6 and EQ-5D VAS scores at T2, compared with baseline. Safety was also assessed.
resultsThe percentage of patients obtaining > 50% reduction in MMDs was 67.4% at T1 (first course) and 73.5% at T2 (second course) for HFEM. For CM the corresponding percentages were 55.9% at T1 and 57.6% at T2. At T2, MMDs were reduced with a significant effect by a median of 9 days from baseline in HFEM, whereas MHDs dropped by a median of 16.5 days in CM patients. A clinically-meaningful improvement in all other effectiveness and disability outcomes was observed at T2, compared to baseline. Quality of life improved by + 87.5% in HFEM and by + 133.3% in CM patients. Response rates favored CGRP-naïve patients in HFEM but not in CM, where outcomes were similar between naïve individuals and prior non-responders. Eptinezumab was generally safe and well-tolerated.
conclusionsEptinezumab 100 mg demonstrated a favorable benefit/risk profile during the 6-month observation period.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.